debrisoquin and paroxetine

debrisoquin has been researched along with paroxetine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J	1
Begley, A; Frye, RF; Kirshner, M; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Solai, LK; Sorisio, D; Sweet, RA	1
Katoh, M; Nakajima, M; Sawada, T; Soeno, Y; Tateno, C; Yokoi, T; Yoshizato, K	1

Trials

2 trial(s) available for debrisoquin and paroxetine

Article	Year
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clinical pharmacology and therapeutics, 2001, Volume: 70, Issue:4 Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Mixed Function Oxygenases; Nortriptyline; Paroxetine; Phenotype; Tremor; Xerostomia	2001
Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:5 Topics: Adrenergic Agents; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Debrisoquin; Depressive Disorder; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Nortriptyline; Paroxetine; Time Factors	2002

Article

Year

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.

Clinical pharmacology and therapeutics, 2001, Volume: 70, Issue:4

Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Mixed Function Oxygenases; Nortriptyline; Paroxetine; Phenotype; Tremor; Xerostomia

2001

Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.

Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:5

Topics: Adrenergic Agents; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Debrisoquin; Depressive Disorder; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Nortriptyline; Paroxetine; Time Factors

2002

Other Studies

2 other study(ies) available for debrisoquin and paroxetine

Article	Year
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. Journal of pharmaceutical sciences, 2007, Volume: 96, Issue:2 Topics: Adrenergic Agents; Animals; Chimera; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Interactions; Humans; Infant; Liver; Male; Mice; Mice, SCID; Models, Animal; Paroxetine; Quinidine; Urokinase-Type Plasminogen Activator	2007

Article

Year

Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.

Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010

In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.

Journal of pharmaceutical sciences, 2007, Volume: 96, Issue:2

Topics: Adrenergic Agents; Animals; Chimera; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Interactions; Humans; Infant; Liver; Male; Mice; Mice, SCID; Models, Animal; Paroxetine; Quinidine; Urokinase-Type Plasminogen Activator

2007